|
McNeil Manufacturing Distress to Drag Into 2013, Constrain 2012 Sales: J&J
Efforts to alleviate manufacturing distress at three McNeil Consumer Healthcare plants will take longer and cost more than expected, forcing the Johnson & Johnson (J&J) subsidiary to trickle out OTC drug products through 2013 and its parent company to sweat over sales in 2012, J&J says.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives